Características de consumo de filgastrim (factor estimulante de colonias de granulocitos) en el servicio de onco-hematología pediátrica del hospital nacional edgardo rebagliati martins- essalud lima, durante el año 2008”
Descripción del Articulo
This work aims to ascertain the know the characteristics of consumption filgastrim (Colony stimulating factor granulocyte), prescribed in the medical service of pediatric hematology-oncology at the Hospital Edgardo Rebagliati Martins in the year 2008, which was a cross-sectional descriptive study, r...
Autor: | |
---|---|
Formato: | tesis de grado |
Fecha de Publicación: | 2009 |
Institución: | Universidad Nacional de Trujillo |
Repositorio: | UNITRU-Tesis |
Lenguaje: | español |
OAI Identifier: | oai:dspace.unitru.edu.pe:20.500.14414/2754 |
Enlace del recurso: | https://hdl.handle.net/20.500.14414/2754 |
Nivel de acceso: | acceso abierto |
Materia: | Factor estimulante de colonias, Estudio de consumo, Dosis diaria prescrita |
Sumario: | This work aims to ascertain the know the characteristics of consumption filgastrim (Colony stimulating factor granulocyte), prescribed in the medical service of pediatric hematology-oncology at the Hospital Edgardo Rebagliati Martins in the year 2008, which was a cross-sectional descriptive study, retrospective drug utilization. We worked with reports from records filgastrim consumption in patients hospitalized in pediatric hematology-oncology HNERM. Of all patients hospitalized in the hematology-oncology patients were treated with 88.31% and 11.69% filgastrim not treated with filgastrim. Regarding the sex of the patients 50.92% were female and 49.08% were male. The increased consumption of filgastrim according to age groups for patients from 0 to 4 years with 43.57%. The most frequent indication was acute lymphoblastic leukemia (C91.0) with 31.22% of total units consumed filgastrim, second malignant tumor was the kidney (C64.X) with 16.54% of total units consumed filgastrim. DDP/100camas-día consumption was expressed as an average of 43.83, the monthly consumption of filgastrim did not show a significant trend to increase or decrease during the study period. The cost of annual consumption was S/. 98 598.03 We conclude that the prevalence of filgastrim was 88.31%, consumption was higher in children under age 5 years, acute lymphocytic leukemia was the diagnosis of increased consumption, the average annual consumption was expressed in DDP/100camas-día 43.83 of the variation in the trend of consumption filgastrim is not a function of time and such variation is not statistically significant during the study period. The annual cost of filgastrim was S/. 98 598.03 |
---|
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).